Synthesize Bio: Valuation, Funding & Investors
Synthesize Bio is a biotechnology company at the forefront of generative genomics, utilizing AI-driven models to simulate gene expression experiments. Their flagship product, Generate Expression Model-1 (GEM-1), is built on an extensive RNA-seq dataset and enables the generation of gene expression data from experimental designs, facilitating drug discovery and scientific research. Founded by scientists from Fred Hutchinson Cancer Center, Synthesize Bio aims to transform biopharmaceutical innovation by providing high-fidelity predictive models that enhance laboratory results and accelerate the development of new therapies.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $10M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $10M
- Latest Funding Round
- Seed Round
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 17, 2025 | Seed Round | $10.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Inner Loop Capital | Seed Round |
| AI2 Incubator | Seed Round |
| Madrona | Seed Round |
| Sahsen Ventures | Seed Round |
| Point Field Partners | Seed Round |
Similar Companies
A snapshot of private companies similar to Synthesize Bio, helping you discover and navigate related company profiles.








